Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listIcotinib

Icotinib

  • CAS NO.:610798-31-7
  • Empirical Formula: C22H21N3O4
  • Molecular Weight: 391.42
  • MDL number: MFCD22124501
  • EINECS: 1592732-453-0
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-07-02 08:55:20
Icotinib Structural

What is Icotinib?

Description

Icotinib is also known as ConMana. It is a highly selective, first-generation inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TKI), whose mutation and overexpression is involved in many kinds of cancer. Icotinib is a quinazoline derivative that binds reversibly to the ATP binding site of the EGFR protein, being capable of blocking the signal transduction cascade. It is currently under investigation for its treatment efficacy on the EGFR+ Non-small cell lung cancer.

The Uses of Icotinib

Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with IC50 of 5 nM.

Indications

Icotinib (Conmana?, BetaPharma), an EGFR inhibitor, was approved by the China State FDA in 2011 for the treatment of NSCLC. Icotinib resembles erlotinib in possessing the N-(3-ethylnylphenyl) quinazolin-4-amine core scaffold of erlotinib that binds to the EGFR ATP pocket. An adjacent hydrophobic group was also retained while the solvent exposed two 2-methoxyethyoxysubstituents at the 6- and 7-positions of the quinazoline core were cyclized to afford the tetraoxacyclododecene moiety of icotinib. Efficacy and safety of icotinib as first-line therapy in patients has been evaluated for advanced NSCLC in recent clinical studies.

General Description

Class: receptor tyrosine kinase
Treatment: NSCLC
Oral bioavailability = 52%
Elimination half-life = 5.5 h

References

Tan, F., et al. "Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. " Lung Cancer76.2(2012):177-82.
Shi, Y., et al. "Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial." Lancet Oncology 14.10(2013):953-61.
Sun, Y., Y. Shi, and L. Zhang. "A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)."Journal of Thoracic Oncology 29.15(2011):-.
https://en.wikipedia.org/wiki/Icotinib

Properties of Icotinib

Boiling point: 581℃
Density  1.31
Flash point: 305℃
storage temp.  Store at -20°C
solubility  insoluble in H2O; ≥129.6 mg/mL in DMSO; ≥14.13 mg/mL in EtOH with ultrasonic
form  Powder
pka 5.32±0.20(Predicted)
color  White to off-white

Safety information for Icotinib

Computed Descriptors for Icotinib

Related products of tetrahydrofuran

You may like

  • Icotinib CAS 610798-31-7
    Icotinib CAS 610798-31-7
    610798-31-7
    View Details
  • Fuel shell 98%
    Fuel shell 98%
    View Details
  • 4,6-dichloro-2-propylthiopyrimidine-5-amine 145783-15-9 98%
    4,6-dichloro-2-propylthiopyrimidine-5-amine 145783-15-9 98%
    145783-15-9
    View Details
  • Hydrogen Gas 98%
    Hydrogen Gas 98%
    View Details
  • 590-17-0 Bromoacetonitrile 98%
    590-17-0 Bromoacetonitrile 98%
    590-17-0
    View Details
  • 151767-02-1 Montelukast Sodium IP/USP 98%
    151767-02-1 Montelukast Sodium IP/USP 98%
    151767-02-1
    View Details
  • Valacyclovir Hydrochloride IH 98%
    Valacyclovir Hydrochloride IH 98%
    124832-27-5
    View Details
  • 2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3- hydroxyl propyl] phenyl]-2-propanol 98%
    2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3- hydroxyl propyl] phenyl]-2-propanol 98%
    142569-70-8
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.